Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12963502 | 0.83 | NPSR1 (0.60) | TSHRALDH1A1NPSR1GFERCHRM1 | |
| SCHEMBL10066394 | 0.80 | NPSR1 (0.63) | TSHRALDH1A1NPSR1GFERCHRM1 | |
| SCHEMBL18997078 | 0.79 | TSHR (0.53) | TSHRALDH1A1NPSR1GFERCHRM1 | |
| SCHEMBL11822716 | 0.79 | KDM1A (0.60) | TSHRALDH1A1NPSR1GFERCHRM1 | |
| SCHEMBL7746872 | 0.79 | TSHR (0.54) | TSHRALDH1A1NPSR1GFERCHRM1 | |
| SCHEMBL8008759 | 0.78 | TSHR (0.55) | TSHRALDH1A1NPSR1GFERCHRM1 | |
| SCHEMBL4101516 | 0.78 | TSHR (0.58) | TSHRALDH1A1NPSR1GFERCHRM1 | |
| SCHEMBL4091216 | 0.77 | NPSR1 (0.54) | TSHRALDH1A1NPSR1GFERCHRM1 | |
| SCHEMBL4095161 | 0.77 | TSHR (0.51) | TSHRALDH1A1NPSR1GFERCHRM1 | |
| SCHEMBL11821877 | 0.77 | CYP2D6 (0.62) | TSHRALDH1A1NPSR1GFERCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | SHY Therapeutics LLC | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | MAPK1, MAPK6, MAP3K1 | TSHR 4428/4885ALDH1A1 2861/4885NPSR1 3741/4885 |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | TSHR 4461/4885ALDH1A1 2765/4885NPSR1 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.